US FDA approves Seqirus' flu vaccine Fluad

Under its accelerated approval regulatory pathway, the US Food and Drug Administration has cleared Fluad, the first seasonal influenza vaccine containing an adjuvant, from Seqiris.

Earlier this year, bioCSL (a unit of Australia’s CSL Limited [ASX:CSL]) and the influenza vaccines unit of Switzerland’s Novartis (NOVN: VX) joined forces to create Seqirus, now the second largest influenza vaccine provider in the world (The Pharma Letter July 31).

Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.